N A Jarad1, I M Sequeiros. 1. Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK. Nabil.Jarad@uhbristol.nhs.uk
Abstract
BACKGROUND: There is currently no simple scoring system to evaluate change in symptoms during a pulmonary exacerbation (PEx) in adult cystic fibrosis (CF) patients. PATIENTS AND METHODS: We evaluated 265 episodes in 58 adult CF patients. A simple symptom score was administered at the start and the end of each PEx. The score evaluated four symptoms: cough, sputum, breathlessness and fatigue. Each symptom was scored from one (mild symptoms) to four (severe symptoms). The total symptom score was the summation of all the four symptoms. The total symptom score was compared with CF Respiratory Questionnaire (CFRQ) and with spirometry. RESULTS: There was significant internal correlation between scores for each pair of symptoms. The total symptom score correlated with the functional activity score and the respiratory score domains and with the summary score for CFRQ. The total symptom score correlated with spirometry values. Symptom score improved after 2-week treatment with intravenous (IV) antibiotics in 88.3%, remained unchanged in 7.3% and worsened in 4.4% of all episodes. Changes in symptom score after IV treatment correlated with changes of all main spirometry measurements. CONCLUSION: This new symptom score is simple and sensitive to change over a short period. It correlates with established quality-of-life questionnaires and with spirometry. The changes of symptom score over a short period correlate with changes in spirometry. This score can be used as an added tool to assess the outcome of CF PExs.
BACKGROUND: There is currently no simple scoring system to evaluate change in symptoms during a pulmonary exacerbation (PEx) in adult cystic fibrosis (CF) patients. PATIENTS AND METHODS: We evaluated 265 episodes in 58 adult CF patients. A simple symptom score was administered at the start and the end of each PEx. The score evaluated four symptoms: cough, sputum, breathlessness and fatigue. Each symptom was scored from one (mild symptoms) to four (severe symptoms). The total symptom score was the summation of all the four symptoms. The total symptom score was compared with CF Respiratory Questionnaire (CFRQ) and with spirometry. RESULTS: There was significant internal correlation between scores for each pair of symptoms. The total symptom score correlated with the functional activity score and the respiratory score domains and with the summary score for CFRQ. The total symptom score correlated with spirometry values. Symptom score improved after 2-week treatment with intravenous (IV) antibiotics in 88.3%, remained unchanged in 7.3% and worsened in 4.4% of all episodes. Changes in symptom score after IV treatment correlated with changes of all main spirometry measurements. CONCLUSION: This new symptom score is simple and sensitive to change over a short period. It correlates with established quality-of-life questionnaires and with spirometry. The changes of symptom score over a short period correlate with changes in spirometry. This score can be used as an added tool to assess the outcome of CF PExs.
Authors: Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume Journal: Thorax Date: 2015-04-24 Impact factor: 9.139
Authors: Fiona J Whelan; Alya A Heirali; Laura Rossi; Harvey R Rabin; Michael D Parkins; Michael G Surette Journal: PLoS One Date: 2017-03-02 Impact factor: 3.240
Authors: Graham Devereux; Danielle Wrolstad; Stephen J Bourke; Cori L Daines; Simon Doe; Ryan Dougherty; Rose Franco; Alastair Innes; Benjamin T Kopp; Jorge Lascano; Daniel Layish; Gordon MacGregor; Lorna Murray; Daniel Peckham; Vincenzina Lucidi; Emma Lovie; Jennifer Robertson; Douglas J Fraser-Pitt; Deborah A O'Neil Journal: PLoS One Date: 2020-12-28 Impact factor: 3.240
Authors: Catherine Ann Byrnes; Suzanna Vidmar; Joyce L Cheney; John B Carlin; David S Armstrong; Peter J Cooper; Keith Grimwood; Marj Moodie; Colin F Robertson; Margaret Rosenfeld; Harm A Tiddens; Claire E Wainwright Journal: Thorax Date: 2013-01-23 Impact factor: 9.139